Alzheimer's Disease Treatment: From Biomarkers to Anti-Amyloid Therapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the accumulation of amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated tau protein in the brain, leading to synaptic dysfunction, neuronal loss, and progressive cognitive decline. It is the most common cause of dementia, accounting for 60–70% of all dementia cases globally, affecting over 55 million people worldwide — a figure projected to reach 153 million by 2050 as the global population ages (WHO 2023).

The AT(N) biomarker framework, introduced by the National Institute on Aging and the Alzheimer's Association (NIA-AA, 2018), defines Alzheimer's disease biologically rather than solely clinically: A = amyloid pathology (abnormal amyloid-42/40 ratio in CSF or positive amyloid PET); T = tau pathology (elevated phospho-tau in CSF or positive tau PET); N = markers of neurodegeneration or neuronal injury (elevated total tau in CSF, FDG-PET hypometabolism, or structural MRI atrophy). This framework enables disease identification in the preclinical phase — before any cognitive symptoms emerge — which is now the target for the earliest and most impactful disease-modifying intervention.

Until 2023, pharmacological management of Alzheimer's disease was purely symptomatic: cholinesterase inhibitors and memantine attenuated symptoms but did not alter the underlying disease trajectory. The FDA approval of lecanemab in January 2023 — followed by donanemab in July 2024 — marked the first treatments to demonstrably slow disease progression by targeting amyloid pathology, representing a fundamental shift in the therapeutic landscape. These approvals are conditional on evidence of amyloid pathology (CSF or PET) and appropriate patient selection, and they introduce a significant new management paradigm including mandatory MRI monitoring for amyloid-related imaging abnormalities (ARIA).

Alzheimer's disease is now understood as a biological continuum that begins decades before clinical symptoms emerge. The NIA-AA 2018 staging framework recognises:

• Preclinical Alzheimer's disease — abnormal AT(N) biomarkers (amyloid and/or tau pathology) in cognitively normal individuals. No functional or cognitive impairment is detectable. This stage may persist for 15–20 years before symptom onset. Currently investigational for disease-modifying therapy; the A3 and AHEAD trials are evaluating early intervention.
• Mild Cognitive Impairment (MCI) due to Alzheimer's disease — biomarker evidence of AD pathology accompanied by objective cognitive decline (usually memory-predominant) that is greater than expected for age, but insufficient to significantly impair independent daily function. Approximately 15% of patients with amnestic MCI progress to dementia annually. MCI due to AD is the primary target population for currently approved anti-amyloid monoclonal antibodies.
• Mild Alzheimer's disease dementia — cognitive impairment sufficient to interfere with daily instrumental activities (managing finances, medications, driving). Memory, language, and executive function are affected. CDR (Clinical Dementia Rating) score of 0.5–1. Both lecanemab and donanemab are approved for early AD including mild dementia.
• Moderate Alzheimer's disease dementia — substantial dependency in instrumental and basic activities of daily living (dressing, hygiene). CDR 2. Cholinesterase inhibitors remain the primary treatment; memantine is added at this stage. Anti-amyloid therapies are not currently approved for moderate or severe AD.
• Severe Alzheimer's disease dementia — loss of most functional independence; limited verbal communication; profound memory impairment; incontinence; swallowing difficulties emerge. CDR 3. Management is palliative — comfort, nutrition, infection prevention, and caregiver support. Memantine alone or in combination with a cholinesterase inhibitor is continued.

Anti-amyloid monoclonal antibodies (lecanemab and donanemab) are approved for a specific, carefully selected patient population. Eligibility criteria include:

• Confirmed amyloid pathology — positive amyloid PET scan (florbetapir, florbetaben, or florbetapir) or CSF demonstrating an abnormal amyloid-42/40 ratio consistent with AD. This biomarker confirmation is mandatory: anti-amyloid therapy cannot be initiated without it.
• Early stage disease — MCI due to AD or mild AD dementia (CDR 0.5 or 1; MMSE typically 20–30). Evidence of efficacy in moderate or severe dementia is absent and these stages are excluded from approved indications.
• Absence of ARIA risk factors — APOE ε4 homozygotes have substantially higher ARIA risk (approximately 40% symptomatic ARIA vs 10–15% in non-carriers) and require particularly careful informed consent, enhanced MRI monitoring, and institutional experience before initiation. Some centres defer treatment in APOE4/4 patients pending further safety data.
• No contraindications to MRI — mandatory MRI surveillance requires MRI compatibility (no ferromagnetic implants, no severe claustrophobia unresponsive to anxiolytics).
• Adequate renal function — both agents require dose adjustment or caution in severe renal impairment given altered drug clearance.
• Absence of recent major intracranial event — recent stroke, cerebral haemorrhage, or significant microhaemorrhage burden on pre-treatment MRI are contraindications or reasons for caution, as ARIA risk is increased.
• Informed consent and caregiver support — the treatment demands biweekly or monthly IV infusions (depending on the agent), regular MRI monitoring, and readiness to manage potential ARIA symptoms. Robust caregiver involvement is essential.

Alzheimer's disease management now encompasses both disease-modifying and symptomatic pharmacological strategies, alongside non-pharmacological interventions.

Anti-Amyloid Monoclonal Antibodies

Lecanemab (Leqembi) — a humanised IgG1 monoclonal antibody targeting soluble amyloid-beta protofibrils. In the CLARITY AD phase 3 trial (van Dyck et al., NEJM, 2023; n=1,795), lecanemab reduced clinical decline by 27% on the CDR-SB (primary endpoint) over 18 months compared to placebo, accompanied by significant amyloid clearance on PET. It received full FDA approval in July 2023. Dosing: 10 mg/kg IV every two weeks.

Donanemab (Kisunla) — a humanised IgG1 monoclonal antibody targeting a modified form of deposited amyloid-beta (pyroglutamate Abeta). In the TRAILBLAZER-ALZ2 phase 3 trial (Sims et al., JAMA, 2023; n=1,736), donanemab reduced clinical decline by 35% on the iADRS (integrated AD Rating Scale) over 76 weeks in the low/medium tau subgroup — participants most likely to benefit. FDA approval granted July 2024. Uniquely, donanemab can be discontinued once amyloid clearance is confirmed on PET (median ~12 months), reducing cumulative drug exposure and potentially cost.

Cholinesterase Inhibitors (ChEIs)

ChEIs remain the standard of care for mild to moderate AD and continue to be used alongside anti-amyloid therapies. They inhibit acetylcholinesterase, increasing synaptic acetylcholine levels in the cortex and hippocampus and modestly improving cognition and function by approximately 2–3 ADAS-Cog points. Three agents are approved: donepezil (5 mg once daily, escalated to 10 mg at 4–6 weeks; 23 mg once daily for severe AD); rivastigmine (oral or transdermal patch; also inhibits butyrylcholinesterase; preferred where GI tolerability is poor via patch formulation); and galantamine (also a nicotinic receptor allosteric potentiator). Common side effects include nausea, vomiting, diarrhoea, bradycardia, and vivid dreams.

Memantine

Memantine is an uncompetitive NMDA receptor antagonist that reduces pathological glutamate-mediated excitotoxicity. Approved for moderate to severe AD, it is often combined with a ChEI at this stage. Modest benefits are seen on cognition, global function, and behaviour. Well-tolerated; principal side effects include dizziness and confusion. Starting dose 5 mg daily, titrated over 4 weeks to the maintenance dose of 20 mg daily.

Combination Therapy

Evidence supports combination ChEI plus memantine in moderate to severe AD. For patients on anti-amyloid therapy, concurrent ChEI use is common and not contraindicated, though evidence for the combination is evolving. Non-pharmacological interventions — cognitive stimulation therapy (CST), structured exercise, social engagement, sleep hygiene, and nutritional optimisation — are recommended at all disease stages.

The benefits of available Alzheimer's treatments span disease modification, symptom management, and quality of life for both patients and caregivers:

• Slowing of disease progression — lecanemab and donanemab each slow clinical decline by approximately 27–35% relative to placebo over 18 months. While this may appear modest in absolute terms, it translates to meaningful delays in milestone events: in the TRAILBLAZER-ALZ2 trial, donanemab delayed progression to the next disease stage by approximately 4.4 months on average — a clinically significant gain in maintained independence.
• Amyloid clearance — both anti-amyloid antibodies produce substantial or complete amyloid plaque clearance on PET imaging in the majority of treated patients. Donanemab achieved amyloid clearance (defined as <24.1 Centiloids) in approximately 76% of participants by 76 weeks — enabling treatment discontinuation in this group, reducing cumulative exposure and cost.
• Symptomatic improvement with ChEIs — cholinesterase inhibitors produce statistically and clinically meaningful improvements in cognitive tests, global function, and activities of daily living in mild to moderate AD. Benefits are maintained for 2–3 years in most responders before disease progression becomes the dominant factor.
• Behavioural symptom management — non-cognitive symptoms of AD (agitation, depression, anxiety, sleep disturbance, apathy) respond to specific pharmacological and non-pharmacological strategies, significantly reducing caregiver burden and enabling patients to remain in community settings longer.
• Caregiver support and delay to institutionalisation — evidence-based comprehensive dementia management programmes incorporating medication, structured activities, social engagement, and caregiver education significantly delay nursing home placement — with substantial economic and quality-of-life implications for patients and families.

Anti-amyloid therapy introduces a new, clinically important adverse effect class — amyloid-related imaging abnormalities (ARIA) — that requires structured management:

ARIA (Amyloid-Related Imaging Abnormalities)

ARIA encompasses two MRI-detected phenomena: ARIA-E (oedema/effusion — T2/FLAIR hyperintensities reflecting vasogenic oedema or sulcal effusion) and ARIA-H (haemosiderin — microhaemorrhages or superficial siderosis). In the CLARITY AD trial, ARIA occurred in 21.3% of lecanemab-treated patients vs 9.3% on placebo; symptomatic ARIA in 2.8% vs 0.9%. In TRAILBLAZER-ALZ2, ARIA occurred in 36.8% vs 14.9%; symptomatic ARIA in 6.1% vs 0.7%. APOE ε4 carriers are at substantially higher risk.

ARIA management by severity:

• Grade 1–2 radiological ARIA (asymptomatic or mild symptoms) — enhanced monitoring with repeat MRI at 4–8 weeks; continue treatment with caution; patient and caregiver education on symptoms to report.
• Grade 3 radiological ARIA or any symptomatic ARIA — hold infusions; repeat MRI every 4 weeks until resolution; resume therapy only when ARIA has resolved on MRI and symptoms have cleared, with close monitoring.
• Grade 4 ARIA or severe/life-threatening symptomatic ARIA — permanently discontinue anti-amyloid therapy; manage symptoms with corticosteroids if clinically indicated; consider MRI-guided monitoring until resolution.

Cholinesterase Inhibitor Adverse Effects

GI side effects (nausea, vomiting, diarrhoea, anorexia) are the most common, particularly during dose escalation; reduced by taking with food and by using the rivastigmine transdermal patch. Cardiovascular effects (bradycardia, sinoatrial block, syncope) require caution in patients with sick sinus syndrome or significant cardiac conduction disease. Rarely, ChEIs may worsen obstructive lung disease or exacerbate peptic ulcers.

Memantine Tolerability

Memantine is generally well tolerated. Side effects include dizziness, headache, constipation, and, in higher doses, mild confusion. It should be used with caution in severe renal impairment (dose reduction required) and in epilepsy (lowers seizure threshold at higher doses).

Structured follow-up is essential for both safety monitoring and to assess therapeutic response:

• Pre-treatment MRI — mandatory brain MRI within 12 months of starting anti-amyloid therapy to establish baseline and exclude clinically significant microhaemorrhage burden, cortical superficial siderosis, or prior cerebrovascular events that would contraindicate treatment.
• ARIA MRI surveillance schedule — for lecanemab: MRI at 26 and 52 weeks. For donanemab: MRI at 24, 52, and 76 weeks. Additional MRI is obtained before each infusion for the first 14 doses for donanemab (per US prescribing information). Any new neurological symptoms prompt unscheduled MRI.
• Amyloid PET for treatment monitoring (donanemab) — repeat amyloid PET at approximately 24 and 52 weeks. When amyloid is confirmed as cleared (<24.1 Centiloids), donanemab infusions are discontinued — a unique feature of this agent's protocol.
• Cognitive and functional assessment — standardised assessments (CDR, MMSE, ADAS-Cog, ADCS-ADL) at 3–6 monthly intervals to document treatment response and disease trajectory. Neuropsychological testing annually.
• Cholinesterase inhibitor review — assessment of GI tolerability and adherence at 4–6 weeks after dose escalation; annual review of continued efficacy versus disease stage.
• Behavioural symptom monitoring — Neuropsychiatric Inventory (NPI) at 6-monthly intervals; prompt management of new behavioural symptoms (agitation, psychosis, sleep disorders, depression) with targeted non-pharmacological strategies first, and pharmacotherapy where required.
• Caregiver assessment — formal caregiver burden assessment and access to support services (Admiral Nursing in the UK, Alzheimer's Association resources internationally) at each visit.

Alzheimer's disease treatment carries significant financial implications, particularly with the introduction of anti-amyloid therapies:

• Anti-amyloid antibody drug costs — lecanemab (Leqembi) is priced at approximately USD 26,500 per year in the United States (as of 2024). Donanemab (Kisunla) carries a similar price point; however, its finite treatment duration (average approximately 12 months until amyloid clearance) may reduce total drug expenditure compared to indefinite lecanemab infusions. These costs are in addition to infusion centre fees and monitoring costs.
• Diagnostic biomarker costs — amyloid PET costs USD 3,000–5,500 per scan in the US (with Medicare coverage now established for appropriate candidates under the Coverage with Evidence Development programme). CSF biomarker analysis costs USD 500–1,500 but is the less expensive alternative where a lumbar puncture is tolerated.
• MRI monitoring costs — mandatory ARIA surveillance requires multiple MRI brain studies over the treatment period. At USD 500–2,500 per scan in US settings, annual monitoring MRI costs add USD 1,000–10,000 depending on the monitoring schedule and local imaging pricing.
• Infusion centre costs — both anti-amyloid agents require intravenous infusion in a clinical setting every 2 or 4 weeks, adding facility fees, nursing costs, and pre-medication expenses to overall treatment cost.
• Symptomatic medication costs — generic donepezil costs USD 10–30 per month; branded extended-release formulations are more expensive. Memantine generics are similarly inexpensive. Rivastigmine patch remains proprietary in some markets, adding to monthly cost.
• Social care and caregiver economic burden — the total economic impact of Alzheimer's care, including informal caregiver time, home care, and residential care costs, substantially exceeds direct medical expenditure. In the US, total societal costs of Alzheimer's care exceed USD 345 billion annually. Access to community dementia support services and carer respite programmes is essential to sustainable management.

Non-pharmacological strategies have an important role across all stages of Alzheimer's disease, and population-level prevention offers the greatest potential to reduce the global burden of dementia.

Cognitive and Social Interventions

Cognitive stimulation therapy (CST) — structured group-based activities stimulating cognitive engagement — has Level A evidence for benefit in mild to moderate dementia and is recommended by NICE (UK). Cognitive rehabilitation, reminiscence therapy, and structured meaningful activity programmes reduce behavioural symptoms and improve quality of life. Social engagement and purpose-driven activity are independently associated with slower cognitive decline in longitudinal studies.

The Lancet Commission 2024: Modifiable Risk Factors

The updated Lancet Commission on Dementia Prevention, Intervention, and Care (2024) identified 14 modifiable risk factors collectively accounting for approximately 45% of dementia cases globally: low education (early life); midlife hypertension, obesity, excessive alcohol consumption, and hearing loss; later-life smoking, depression, physical inactivity, social isolation, diabetes, air pollution, traumatic brain injury, hypercholesterolaemia, and vision loss. Addressing these risk factors through public health and individual-level interventions offers the single greatest opportunity to reduce dementia incidence — potentially preventing or delaying millions of cases annually.

MIND Diet

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) combines elements of the Mediterranean and DASH diets with a specific focus on brain-protective foods. Prospective observational data (Morris et al., Alzheimer's and Dementia, 2015) associate strict MIND diet adherence with a 53% lower rate of AD, and moderate adherence with 35% lower risk. Key components include leafy greens, other vegetables, berries, nuts, olive oil, whole grains, fish, legumes, poultry, and wine in moderation — with red meat, butter, cheese, pastries, and fried foods limited.

Exercise

Aerobic exercise produces hippocampal volume increases and improves performance on cognitive tests in randomised controlled trials. A minimum of 150 minutes per week of moderate-intensity aerobic exercise is recommended for cardiovascular and cognitive health across all age groups. Resistance training additionally improves executive function and has independent neuroprotective effects.

Clinical Trials

For patients motivated to access emerging therapies, enrolment in clinical trials evaluating next-generation anti-amyloid agents, tau-targeting antibodies, synaptic function enhancers, and combination therapy strategies should be discussed as a legitimate and actively encouraged option at all disease stages.